BREA, Calif., Feb. 7, 2024 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) today announced results for the fourth quarter and full year 2023.
For the quarter ended December 31, 2023, reported sales were $645.6 million. Core sales in the quarter declined 2.0% over the corresponding quarter in 2022. Net loss in the fourth quarter was $217.4 million or $1.27 per diluted share. The net loss included a $258.3 million non-cash charge related to the impairment of goodwill and intangible assets. During the same period, adjusted net income was $49.7 million or $0.29 per diluted share compared to adjusted net income of $91.9 million or $0.52 per diluted share in the same period of 2022. Adjusted EBITDA for the fourth quarter of 2023 was $100.5 million compared to $138.3 million in the fourth quarter of 2022.
Amir Aghdaei, Chief Executive Officer, stated, "Despite a volatile macro backdrop in 2023, the Envista team delivered full year results in line with our expectations. For the full year 2023, we saw a modest decline in core growth and delivered an adjusted EBITDA margin of 18.1%. Our Orthodontic business continues to outperform, growing double digits for the full year 2023, with Spark Aligner growing over 50%. We further delivered $223.6 million of free cash flow for the full year, representing an increase of more than $100 million over 2022."
Mr. Aghdaei continued, "We are committed to our purpose of partnering with dental professionals to improve patients' lives by digitizing, personalizing, and democratizing dental care. 2024 will be a transformational year for Envista as we focus on improving Spark profitability, accelerating our North American implant business, and optimizing our operating structure using the Envista Business System. Long-term, we remain focused on delivering value for patients, our customers, our employees, and our shareholders."
2024 Guidance
For the full year 2024, we expect core sales to grow low-single digits and to deliver adjusted EBITDA margins of between 16% - 17%. We further anticipate that our margins will accelerate as we move through 2024. Our guidance takes into consideration both our investments for the long-term and the continued uncertainty in the macro environment.
Please note, we do not provide forward-looking estimates on a GAAP basis as certain information is not available and cannot be reasonably estimated.
Envista will discuss its quarterly results and provide an outlook for 2024 during an investor conference call today starting at 2:00 P.M. PT. The call and an accompanying slide presentation will be webcast on the "Investors" section of Envista's website, www.envistaco.com, under the subheading "Events & Presentations." A replay of the webcast will be available in the same section of Envista's website shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call.
The conference call can be accessed by 800-225-9448 within the U.S. or +1 203-518-9708 outside the U.S. a few minutes before 2:00 PM PT and referencing conference ID #7305894. A replay of the conference call will be available shortly after the conclusion of the call. You can access the replay dial-in information on the "Investors" section of Envista's website under the subheading "Events & Presentations." Presentation materials relating to Envista's results have been posted to the "Investors" section of Envista's website under the subheading "Quarterly Earnings."
ABOUT ENVISTA
Envista is a global family of more than 30 trusted dental brands, including Nobel Biocare, Ormco, DEXIS, and Kerr united by a shared purpose: to partner with professionals to improve lives. Envista helps its customers deliver the best possible patient care through industry-leading dental consumables, solutions, technology, and services. Our comprehensive portfolio, including dental implants and treatment options, orthodontics, and digital imaging technologies, covers a wide range of dentists' clinical needs for diagnosing, treating, and preventing dental conditions as well as improving the aesthetics of the human smile. With a foundation comprised of the proven Envista Business System (EBS) methodology, an experienced leadership team, and a strong culture grounded in continuous improvement, commitment to innovation, and deep customer focus, Envista is well equipped to meet the end-to-end needs of dental professionals worldwide. Envista is one of the largest global dental products companies, with significant market positions in some of the most attractive segments of the dental products industry. For more information, please visit www.envistaco.com.
NON-GAAP MEASURES
All "Adjusted" amounts including core sales growth and free cash flow are non-GAAP items. Calculations of these measures, the reasons why we believe these measures provide useful information to investors, a reconciliation of these measures to the most directly comparable GAAP measures, and other information relating to these non-GAAP measures are included in the attached supplemental schedules. We do not reconcile forward looking non-GAAP measures to the comparable GAAP measures because of the inherent difficulty in predicting and estimating the future impact and timing of currency translation, acquisitions, discontinued products, and any other potential adjustments which would be reflected in any forecasted GAAP measure.
FORWARD-LOOKING STATEMENTS
Certain statements in this press release are "forward-looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things, the conditions in the U.S. and global economy, the impact of inflation and increasing interest rates, international economic, political, legal, compliance and business factors, the markets served by us and the financial markets, the impact of the COVID-19 pandemic, the impact of our debt obligations on our operations and liquidity, developments and uncertainties in trade policies and regulations, contractions or growth rates and cyclicality of markets we serve, risks relating to product manufacturing, commodity costs and surcharges, our ability to adjust purchases and manufacturing capacity to reflect market conditions, reliance on sole or limited sources of supply, disruptions relating to war, terrorism, climate change, widespread protests and civil unrest, man-made and natural disasters, public health issues and other events, security breaches or other disruptions of our information technology systems or violations of data privacy laws, fluctuations in inventory of our distributors and customers, loss of a key distributor, our relationships with and the performance of our channel partners, competition, our ability to develop and successfully market new products and services, our ability to attract, develop and retain our key personnel, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including regulations relating to medical devices and the health care industry), the results of our clinical trials and perceptions thereof, penalties associated with any off-label marketing of our products, modifications to our products that require new marketing clearances or authorizations, our ability to effectively address cost reductions and other changes in the health care industry, our ability to successfully identify and consummate appropriate acquisitions and strategic investments, our ability to integrate the businesses we acquire and achieve the anticipated benefits of such acquisitions, contingent liabilities relating to acquisitions, investments and divestitures, our ability to adequately protect our intellectual property, the impact of our restructuring activities on our ability to grow, risks relating to currency exchange rates, changes in tax laws applicable to multinational companies, litigation and other contingent liabilities including intellectual property and environmental, health and safety matters, risks relating to product, service or software defects, the impact of regulation on demand for our products and services, and labor matters. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our Annual Report on Form 10-K for fiscal year 2022 and our Quarterly reports on Form 10-Q. These forward-looking statements speak only as of the date of this press release and except to the extent required by applicable law, we do not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.
CONTACT
Stephen Keller
Principal Financial Officer
Envista Holdings Corporation
200 S. Kraemer Blvd., Building E
Brea, CA 92821
Telephone: (714) 817-7000
ENVISTA HOLDINGS CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) ($ and shares in millions, except per share amounts) | |||||||
Three Months Ended | Twelve Months Ended | ||||||
December 31, 2023 | December 31, 2022 | December 31, 2023 | December 31, 2022 | ||||
Sales | $ 645.6 | $ 660.8 | $ 2,566.5 | $ 2,569.1 | |||
Cost of sales | 309.7 | 294.6 | 1,126.0 | 1,094.3 | |||
Gross profit | 335.9 | 366.2 | 1,440.5 | 1,474.8 | |||
Operating expenses: | |||||||
Selling, general and administrative | 260.2 | 253.6 | 1,056.9 | 1,055.5 | |||
Research and development | 20.2 | 24.6 | 93.8 | 100.1 | |||
Goodwill and intangible asset impairment | 258.3 | — | 258.3 | — | |||
Operating (loss) profit | (202.8) | 88.0 | 31.5 | 319.2 | |||
Nonoperating income (expense): | |||||||
Other income (expense) | 1.7 | 2.2 | (23.0) | 3.1 | |||
Interest expense, net | (13.9) | (14.5) | (63.4) | (38.4) | |||
(Loss) income before income taxes | (215.0) | 75.7 | (54.9) | 283.9 | |||
Income tax expense | 2.4 | 2.2 | 45.3 | 45.9 | |||
(Loss) income from continuing operations, net of tax | (217.4) | 73.5 | (100.2) | 238.0 | |||
Income from discontinued operations, net of tax | — | — | — | 5.1 | |||
Net (loss) income | $ (217.4) | $ 73.5 | $ (100.2) | $ 243.1 | |||
Earnings per share: | |||||||
(Loss) earnings from continuing operations - basic | $ (1.27) | $ 0.45 | $ (0.60) | $ 1.46 | |||
(Loss) earnings from continuing operations - diluted | $ (1.27) | $ 0.42 | $ (0.60) | $ 1.34 | |||
Earnings from discontinued operations - basic | $ — | $ — | $ — | $ 0.03 | |||
Earnings from discontinued operations - diluted | $ — | $ — | $ — | $ 0.03 | |||
(Loss) earnings - basic | $ (1.27) | $ 0.45 | $ (0.60) | $ 1.49 | |||
(Loss) earnings - diluted | $ (1.27) | $ 0.42 | $ (0.60) | $ 1.37 | |||
Average common stock and common equivalent shares outstanding: | |||||||
Basic | 171.7 | 163.3 | 166.9 | 162.9 | |||
Diluted | 171.7 | 175.3 | 166.9 | 177.6 | |||
ENVISTA HOLDINGS CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) ($ in millions, except share amounts) | |||
As of | |||
December 31, 2023 | December 31, 2022 | ||
ASSETS | |||
Current assets: | |||
Cash and cash equivalents | $ 940.0 | $ 606.9 | |
Trade accounts receivable, less allowance for credit losses of $17.3 and $16.2, | 407.5 | 393.5 | |
Inventories, net | 258.8 | 300.8 | |
Prepaid expenses and other current assets | 137.4 | 123.4 | |
Total current assets | 1,743.7 | 1,424.6 | |
Property, plant and equipment, net | 309.6 | 293.6 | |
Operating lease right-of-use assets | 125.1 | 131.8 | |
Other long-term assets | 180.5 | 153.7 | |
Goodwill | 3,292.2 | 3,496.6 | |
Other intangible assets, net | 954.0 | 1,086.7 | |
Total assets | $ 6,605.1 | $ 6,587.0 | |
LIABILITIES AND EQUITY | |||
Current liabilities: | |||
Short-term debt | $ 115.3 | $ 510.0 | |
Trade accounts payable | 179.5 | 228.3 | |
Accrued expenses and other liabilities | 455.7 | 471.4 | |
Operating lease liabilities | 30.3 | 27.0 | |
Total current liabilities | 780.8 | 1,236.7 | |
Operating lease liabilities | 109.9 | 121.4 | |
Other long-term liabilities | 142.4 | 151.3 | |
Long-term debt | 1,398.1 | 870.7 | |
Commitments and contingencies | |||
Stockholders' equity: | |||
Preferred stock, $0.01 par value, 15.0 million shares authorized; no shares issued | — | — | |
Common stock - $0.01 par value, 500.0 million shares authorized; 173.3 million | 1.7 | 1.6 | |
Additional paid-in capital | 3,758.2 | 3,699.0 | |
Retained earnings | 631.2 | 731.4 | |
Accumulated other comprehensive loss | (217.2) | (225.1) | |
Total stockholders' equity | 4,173.9 | 4,206.9 | |
Total liabilities and stockholders' equity | $ 6,605.1 | $ 6,587.0 | |
ENVISTA HOLDINGS CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) ($ in millions) | |||||
Year Ended December 31, | |||||
2023 | 2022 | 2021 | |||
Cash flows from operating activities: | |||||
Net (loss) income | $ (100.2) | $ 243.1 | $ 340.5 | ||
Noncash items: | |||||
Depreciation | 36.0 | 31.8 | 40.8 | ||
Amortization | 99.6 | 106.0 | 82.8 | ||
Allowance for credit losses | 7.1 | 4.8 | 5.6 | ||
Stock-based compensation expense | 30.7 | 30.5 | 28.2 | ||
Gain on equity investments, net | (3.6) | — | — | ||
Gain on sale of property, plant and equipment | (5.4) | (1.9) | (2.2) | ||
Gain on sale of KaVo treatment unit and instrument business | — | (8.9) | (11.7) | ||
Restructuring charges | 1.3 | 4.7 | 10.8 | ||
Goodwill and intangible asset impairment | 258.3 | — | — | ||
Other impairment charges | 0.2 | 6.4 | 18.4 | ||
Fair value adjustment of acquisition-related inventory | — | 9.5 | — | ||
Amortization of right-of-use assets | 27.0 | 24.3 | 28.3 | ||
Inducement expense related to exchange of convertible notes | 28.5 | — | — | ||
Amortization of debt discount and issuance costs | 4.6 | 4.1 | 23.3 | ||
Change in deferred income taxes | (37.0) | (29.0) | (59.0) | ||
Change in trade accounts receivable | (17.0) | (71.0) | (43.2) | ||
Change in inventories | 35.1 | (39.9) | (66.0) | ||
Change in trade accounts payable | (46.3) | 44.5 | (20.3) | ||
Change in prepaid expenses and other assets | 16.8 | (11.7) | (11.5) | ||
Change in accrued expenses and other liabilities | (25.5) | (133.0) | 34.3 | ||
Change in operating lease liabilities | (34.5) | (31.6) | (37.5) | ||
Net cash provided by operating activities | 275.7 | 182.7 | 361.6 | ||
Cash flows from investing activities: | |||||
Payments for additions to property, plant and equipment | (58.2) | (75.7) | (54.7) | ||
Proceeds from sales of property, plant and equipment | 6.1 | 3.3 | 11.6 | ||
Proceeds from sale of equity investment | 10.7 | — | — | ||
Acquisitions, net of cash acquired | — | (696.2) | (2.1) | ||
Proceeds from sale of KaVo treatment unit and instrument business, net | — | 73.9 | 312.5 | ||
Proceeds from the settlement of derivative financial instruments | 1.6 | 56.0 | 11.4 | ||
All other investing activities, net | (22.6) | (18.6) | (16.0) | ||
Net cash (used in) provided by investing activities | (62.4) | (657.3) | 262.7 | ||
Cash flows from financing activities: | |||||
Proceeds from issuance of convertible notes due 2028 | 500.2 | — | — | ||
Debt issuance costs related to issuance of convertible notes due 2028 | (13.8) | — | — | ||
Principal paid related to exchange of convertible notes due 2025 | (401.2) | — | — | ||
Proceeds from borrowings | 323.5 | 0.3 | — | ||
Repayment of borrowings | (288.8) | (0.5) | (475.7) | ||
Debt issuance costs related to other borrowings | (4.5) | — | (2.3) | ||
Proceeds from revolving line of credit | — | 124.0 | — | ||
Repayment of revolving line of credit | — | (124.0) | — | ||
Proceeds from stock option exercises | 11.3 | 21.8 | 19.5 | ||
Tax withholding payment related to net settlement of equity awards | (7.9) | (9.1) | (7.2) | ||
All other financing activities | 0.1 | — | 0.1 | ||
Net cash provided by (used in) financing activities | 118.9 | 12.5 | (465.6) | ||
Effect of exchange rate changes on cash and cash equivalents | 0.9 | (4.6) | 26.0 | ||
Net change in cash and cash equivalents | 333.1 | (466.7) | 184.7 | ||
Beginning balance of cash and cash equivalents | 606.9 | 1,073.6 | 888.9 | ||
Ending balance of cash and cash equivalents | $ 940.0 | $ 606.9 | $ 1,073.6 | ||
ENVISTA HOLDINGS CORPORATION SUMMARY OF FINANCIAL METRICS (Unaudited) ($ in millions, except per share amounts) | |||||||
GAAP | |||||||
Three Months Ended | Year Ended | ||||||
December 31, 2023 | December 31, 2022 | December 31, 2023 | December 31, 2022 | ||||
Gross Profit | $ 335.9 | $ 366.2 | $ 1,440.5 | $ 1,474.8 | |||
Operating (Loss) Profit From Continuing Operations | $ (202.8) | $ 88.0 | $ 31.5 | $ 319.2 | |||
Net (Loss) Income From Continuing Operations | $ (217.4) | $ 73.5 | $ (100.2) | $ 238.0 | |||
(Loss) Diluted Earnings Per Share From Continuing Operations | $ (1.27) | $ 0.42 | $ (0.60) | $ 1.34 | |||
Operating Cash Flow | $ 102.0 | $ 110.3 | $ 275.7 | $ 182.7 | |||
NON-GAAP * | |||||||
Three Months Ended | Year Ended | ||||||
December 31, 2023 | December 31, 2022 | December 31, 2023 | December 31, 2022 | ||||
Adjusted Gross Profit | $ 338.6 | $ 371.6 | $ 1,450.5 | $ 1,497.9 | |||
Adjusted Operating Profit | $ 89.6 | $ 128.2 | $ 425.8 | $ 482.5 | |||
Adjusted Net Income | $ 49.7 | $ 91.9 | $ 269.2 | $ 345.3 | |||
Adjusted Diluted EPS | $ 0.29 | $ 0.52 | $ 1.53 | $ 1.94 | |||
Adjusted EBITDA | $ 100.5 | $ 138.3 | $ 464.2 | $ 517.4 | |||
Free Cash Flow | $ 99.9 | $ 95.1 | $ 223.6 | $ 110.3 | |||
* For information on non-GAAP measures see "Reconciliation of GAAP to Non-GAAP Financial Measures" below. Also see the accompanying "Notes to Reconciliation of GAAP to Non-GAAP Financial Measures." |
ENVISTA HOLDINGS CORPORATION SEGMENT INFORMATION (Unaudited) ($ in millions) | |||||||
Three Months Ended | Year Ended | ||||||
December 31, 2023 | December 31, 2022 | December 31, 2023 | December 31, 2022 | ||||
Sales | |||||||
Specialty Products & Technologies | $ 415.9 | $ 398.4 | $ 1,642.4 | $ 1,598.6 | |||
Equipment & Consumables | 229.7 | 262.4 | 924.1 | 970.5 | |||
Total | $ 645.6 | $ 660.8 | $ 2,566.5 | $ 2,569.1 | |||
Operating (Loss) Profit | |||||||
Specialty Products & Technologies | $ 43.9 | $ 62.0 | $ 232.1 | $ 268.6 | |||
Equipment & Consumables | 31.5 | 52.0 | 156.3 | 172.4 | |||
Other | (278.2) | (26.0) | (356.9) | (121.8) | |||
Total | $ (202.8) | $ 88.0 | $ 31.5 | $ 319.2 | |||
Operating Margins | |||||||
Specialty Products & Technologies | 10.6 % | 15.6 % | 14.1 % | 16.8 % | |||
Equipment & Consumables | 13.7 % | 19.8 % | 16.9 % | 17.8 % | |||
Total | (31.4) % | 13.3 % | 1.2 % | 12.4 % | |||
ENVISTA HOLDINGS CORPORATION RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (UNAUDITED) ($ in millions, except per share amounts) | |||||||
Adjusted Gross Profit and Adjusted Gross Margin | Three Months Ended | Year Ended | |||||
December 31, | December 31, | December 31, | December 31, | ||||
Gross Profit | $ 335.9 | $ 366.2 | $ 1,440.5 | $ 1,474.8 | |||
Restructuring costs and asset impairments B | 2.7 | 3.6 | 10.0 | 13.6 | |||
Fair value adjustment of acquisition-related inventory D | — | 1.8 | — | 9.5 | |||
Adjusted Gross Profit | $ 338.6 | $ 371.6 | $ 1,450.5 | $ 1,497.9 | |||
Gross Margin (Gross Profit / Sales) | 52.0 % | 55.4 % | 56.1 % | 57.4 % | |||
Adjusted Gross Margin (Adjusted Gross Profit / Sales) | 52.4 % | 56.2 % | 56.5 % | 58.3 % | |||
Adjusted Operating Profit | Three Months Ended | Year Ended | |||||
December 31, | December 31, | December 31, | December 31, | ||||
Consolidated | |||||||
Operating (Loss) Profit | $ (202.8) | $ 88.0 | $ 31.5 | $ 319.2 | |||
Goodwill and intangible asset impairment A | 258.3 | — | 258.3 | — | |||
Amortization of acquisition-related and other intangible assets | 23.7 | 27.8 | 99.6 | 106.0 | |||
Restructuring costs and asset impairments B | 10.4 | 9.5 | 35.1 | 37.6 | |||
Acquisition related expenses C | — | 1.1 | 1.3 | 15.7 | |||
Fair value adjustment of acquisition-related inventory D | — | 1.8 | — | 9.5 | |||
Contingent loss reserves G | — | — | — | 1.0 | |||
International tax credit H | — | — | — | (6.5) | |||
Adjusted Operating Profit | $ 89.6 | $ 128.2 | $ 425.8 | $ 482.5 | |||
Adjusted Operating Profit as a % of Sales | 13.9 % | 19.4 % | 16.6 % | 18.8 % | |||
Specialty Products & Technologies | |||||||
Operating Profit | $ 43.9 | $ 62.0 | $ 232.1 | $ 268.6 | |||
Amortization of acquisition-related and other intangible assets | 15.5 | 15.5 | 62.8 | 60.2 | |||
Restructuring costs and asset impairments B | 4.5 | 2.0 | 14.0 | 14.7 | |||
Contingent loss reserves G | — | — | — | 1.0 | |||
International tax credit H | — | — | — | (1.7) | |||
Adjusted Operating Profit | $ 63.9 | $ 79.5 | $ 308.9 | $ 342.8 | |||
Adjusted Operating Profit as a % of Sales | 15.4 % | 20.0 % | 18.8 % | 21.4 % | |||
Equipment & Consumables | |||||||
Operating Profit | $ 31.5 | $ 52.0 | $ 156.3 | $ 172.4 | |||
Amortization of acquisition-related and other intangible assets | 8.2 | 12.3 | 36.8 | 45.8 | |||
Restructuring costs and asset impairments B | 5.0 | 7.1 | 19.0 | 19.7 | |||
International tax credit H | — | — | — | (4.8) | |||
Adjusted Operating Profit | $ 44.7 | $ 71.4 | $ 212.1 | $ 233.1 | |||
Adjusted Operating Profit as a % of Sales | 19.5 % | 27.2 % | 23.0 % | 24.0 % | |||
See the accompanying Notes to Reconciliation of GAAP to Non-GAAP Financial Measures | |||||||
Adjusted Net Income | |||||||
Three Months Ended | Year Ended | ||||||
December 31, | December 31, | December 31, | December 31, | ||||
Net (Loss) Income From Continuing Operations | $ (217.4) | $ 73.5 | $ (100.2) | $ 238.0 | |||
Goodwill and intangible asset impairment A | 258.3 | — | 258.3 | — | |||
Amortization of acquisition-related and other intangible assets | 23.7 | 27.8 | 99.6 | 106.0 | |||
Restructuring costs and asset impairments B | 10.4 | 9.5 | 35.1 | 37.6 | |||
Acquisition related expenses C | — | 1.1 | 1.3 | 15.7 | |||
Fair value adjustment of acquisition-related inventory D | — | 1.8 | — | 9.5 | |||
Gain on equity investments, net E | — | — | (3.6) | — | |||
Inducement and other expenses related to convertible notes exchange F | — | — | 29.0 | — | |||
Contingent loss reserves G | — | — | — | 1.0 | |||
International tax credit H | — | — | — | (6.5) | |||
Tax effect of adjustments reflected above I | (14.2) | (9.6) | (39.7) | (38.0) | |||
Discrete tax adjustments and other tax-related adjustments J | (11.1) | (12.2) | (10.6) | (18.0) | |||
Adjusted Net Income | $ 49.7 | $ 91.9 | $ 269.2 | $ 345.3 | |||
Adjusted Diluted Earnings Per Share | |||||||
Three Months Ended | Year Ended | ||||||
December 31, | December 31, | December 31, | December 31, | ||||
(Loss) Diluted Earnings From Continuing Operations Per Share | $ (1.27) | $ 0.42 | $ (0.60) | $ 1.34 | |||
Goodwill and intangible asset impairment A | 1.49 | — | 1.47 | — | |||
Amortization of acquisition-related and other intangible assets | 0.14 | 0.16 | 0.57 | 0.60 | |||
Restructuring costs and asset impairments B | 0.06 | 0.05 | 0.20 | 0.21 | |||
Acquisition related expenses C | — | 0.01 | 0.01 | 0.09 | |||
Fair value adjustment of acquisition-related inventory D | — | 0.01 | — | 0.05 | |||
Gain on equity investments, net E | — | — | (0.02) | — | |||
Inducement and other expenses related to convertible notes exchange F | — | — | 0.17 | — | |||
Contingent loss reserves G | — | — | — | 0.01 | |||
International tax credit H | — | — | — | (0.04) | |||
Tax effect of adjustments reflected above I | (0.08) | (0.05) | (0.23) | (0.21) | |||
Discrete tax adjustments and other tax-related adjustments J | (0.06) | (0.08) | (0.06) | (0.11) | |||
Net (loss) to adjusted net income share adjustment K | 0.01 | — | 0.02 | — | |||
Adjusted Diluted Earnings Per Share | $ 0.29 | $ 0.52 | $ 1.53 | $ 1.94 | |||
Adjusted Diluted Shares Outstanding | |||||||
Three Months Ended | Year Ended | ||||||
December 31, | December 31, | December 31, | December 31, | ||||
Average common stock shares outstanding - basic | 171.7 | 163.3 | 166.9 | 162.9 | |||
Assumed exercise of dilutive options and vesting of | 1.8 | 12.0 | 8.7 | 14.7 | |||
Average common stock and common equivalent shares | 173.5 | 175.3 | 175.6 | 177.6 | |||
Adjusted EBITDA | |||||||
Three Months Ended | Year Ended | ||||||
December 31, | December 31, | December 31, | December 31, | ||||
Net (Loss) Income From Continuing Operations | $ (217.4) | $ 73.5 | $ (100.2) | $ 238.0 | |||
Interest expense, net | 13.9 | 14.5 | 63.4 | 38.4 | |||
Income tax expense | 2.4 | 2.2 | 45.3 | 45.9 | |||
Depreciation | 9.2 | 7.9 | 36.0 | 31.8 | |||
Goodwill and intangible asset impairment A | 258.3 | — | 258.3 | — | |||
Amortization of acquisition-related and other intangible assets | 23.7 | 27.8 | 99.6 | 106.0 | |||
Restructuring costs and asset impairments B | 10.4 | 9.5 | 35.1 | 37.6 | |||
Acquisition related expenses C | — | 1.1 | 1.3 | 15.7 | |||
Fair value adjustment of acquisition-related inventory D | — | 1.8 | — | 9.5 | |||
Gain on equity investments, net E | — | — | (3.6) | — | |||
Inducement and other expenses related to convertible notes exchange F | — | — | 29.0 | — | |||
Contingent loss reserves G | — | — | — | 1.0 | |||
International tax credit H | — | — | — | (6.5) | |||
Adjusted EBITDA | $ 100.5 | $ 138.3 | $ 464.2 | $ 517.4 | |||
Adjusted EBITDA as a % of Sales | 15.6 % | 20.9 % | 18.1 % | 20.1 % | |||
See the accompanying Notes to Reconciliation of GAAP to Non-GAAP Financial Measures | |||||||
Core Sales Growth 1 | |||
Consolidated | % Change Three | % Change Twelve | |
Total sales growth | (2.3) % | (0.1) % | |
Plus the impact of: | |||
Acquisitions | — % | (1.2) % | |
Currency exchange rates | 0.3 % | 0.9 % | |
Core sales growth | (2.0) % | (0.4) % | |
Specialty Products & Technologies | |||
Total sales growth | 4.4 % | 2.7 % | |
Plus the impact of: | |||
Acquisitions | — % | (1.1) % | |
Currency exchange rates | 0.4 % | 1.3 % | |
Core sales growth | 4.8 % | 2.9 % | |
Equipment & Consumables | |||
Total sales growth | (12.5) % | (4.8) % | |
Plus the impact of: | |||
Acquisitions | — % | (1.5) % | |
Currency exchange rates | 0.1 % | 0.4 % | |
Core sales growth | (12.4) % | (5.9) % |
1 | We use the term "core sales" to refer to GAAP revenue excluding (1) sales from acquired businesses recorded prior to the first anniversary of the acquisition ("acquisitions"), (2) sales from discontinued products and (3) the impact of currency translation. Sales from discontinued products includes major brands or products that Envista has made the decision to discontinue as part of a portfolio restructuring. Discontinued brands or products consist of those which Envista (1) is no longer manufacturing, (2) is no longer investing in the research or development of, and (3) expects to discontinue all significant sales within one year from the decision date to discontinue. The portion of sales attributable to discontinued brands or products is calculated as the net decline of the applicable discontinued brand or product from period-to-period. The portion of GAAP revenue attributable to currency exchange rates is calculated as the difference between (a) the period-to-period change in sales and (b) the period-to-period change in sales after applying current period foreign exchange rates to the prior year period. We use the term "core sales growth" to refer to the measure of comparing current period core sales with the corresponding period of the prior year. |
Reconciliation of Operating Cash Flows to Free Cash Flow | |||||||
Three Months Ended | Year Ended | ||||||
December 31, | December 31, | December 31, | December 31, | ||||
Net Operating Cash Provided by Operating Activities | $ 102.0 | $ 110.3 | $ 275.7 | $ 182.7 | |||
Less: payments for additions to property, plant and | (8.2) | (16.9) | (58.2) | (75.7) | |||
Plus: proceeds from sales of property, plant and equipment | 6.1 | 1.7 | 6.1 | 3.3 | |||
Free Cash Flow | $ 99.9 | $ 95.1 | $ 223.6 | $ 110.3 | |||
See the accompanying Notes to Reconciliation of GAAP to Non-GAAP Financial Measures | |||||||
ENVISTA HOLDINGS CORPORATION | |
A | Represents impairment charge related to goodwill and certain indefinite-lived intangibles. |
B | We exclude costs incurred pursuant to discrete restructuring plans that are fundamentally different (in terms of the size, strategic nature and planning requirements) from the ongoing productivity improvements that result from application of the Envista Business System. These restructuring plans are incremental to the operating activities that arise in the ordinary course of our business and we believe are not indicative of Envista's ongoing operating costs in a given period. |
C | These represent acquisition related transactions expenses and integration costs with respect to business combinations. |
D | Represents the fair value adjustment related to inventory acquired in connection with acquisitions. |
E | Represents gains or losses on equity investments. |
F | These costs primarily relate to inducement and other expenses incurred in connection with our partial exchange of our 2025 Convertible Senior Notes. |
G | Represents accruals for certain legal matters. |
H | Represents international tax credit related to a ruling from the Brazilian Supreme Court. |
I | This line item reflects the aggregate tax effect of all pretax adjustments reflected in the preceding line items of the table using each adjustment's applicable tax rate, including the effect of interim tax accounting requirements of Accounting Standards Codification Topic 740 Income Taxes. |
J | The discrete tax matters relate primarily to excess tax benefits from stock-based compensation, changes in estimates associated with prior period uncertain tax positions and audit settlements, tax benefits resulting from a change in law, and changes in determination of realization of certain deferred tax assets. |
K | The Company was in a net loss position for the three and twelve months ended December 31, 2023, therefore no shares reserved for issuance upon exercise of stock options, vesting of restricted stock and performance stock units or assumed conversion of the convertible senior notes due 2025 were included in the computation of diluted loss per share as their inclusion would have been anti-dilutive. However, given that the adjustments noted in footnotes A-J resulted in adjusted net income for the three and twelve months ended December 31, 2023, the dilutive impact of stock options, restricted stock and performance stock units and assumed conversion of the convertible senior secured notes due 2025 is being included to arrive at adjusted diluted shares outstanding. |
Statement Regarding Non-GAAP Measures
Each of the non-GAAP measures set forth above should be considered in addition to, and not as a replacement for or superior to, the comparable GAAP measure, and may not be comparable to similarly titled measures reported by other companies. Management believes that these measures provide useful information to investors by offering additional ways of viewing Envista Holdings Corporation's ("Envista" or the "Company") results that, when reconciled to the corresponding GAAP measure, help our investors to:
Management uses these non-GAAP measures to measure the Company's operating and financial performance.
The items excluded from the non-GAAP measures set forth above have been excluded for the following reasons:
| Last Trade: | US$20.39 |
| Daily Change: | 0.37 1.85 |
| Daily Volume: | 1,769,777 |
| Market Cap: | US$3.500B |
April 15, 2024 March 19, 2024 February 12, 2024 December 14, 2023 November 01, 2023 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
